Paydirt
AP
Insider

AH Bio Fund II, L.P.

10% owner

AH Bio Fund II, L.P. (10% owner) filed 2 Form 4 reports as a reporting entity in the trailing twelve months (1 purchase, 1 sale), most often in NAUT. Across 1 priced purchase filing, the average 21-session return was +73.4% from execution and +75.6% from disclosure (delay-adjusted; derived). The largest single filing was $11.8M of NAUT (5,000,000 sh across 2 lots, as filed), executed Jun 2.

Add to watchlist
Return, ttmiAverage return per filing, trailing twelve months
+73.4%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+75.6%
same 1 filings, from disclosure
Filings, ttm
2
1 buys · 1 sells
Median delay
2d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$16.7M
shares × price, as filed
Last traded
Jul 27
Filed Jul 29

Median ADV $11.1M across their filed names

Open performance
Volume by month
$11.8M$5.9M$0Oct 2024Apr 2025Oct 2025Apr 2026Jun 2026 · sells $11.8MJul 2026 · buys $5.0M
Buys $5.0M Sells $11.8M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on
Healthcare 1 filing Not on file 1 filing

Sector per market data · by filing · past 12 months

Most traded names
NAUT NAUT NAUT · 0 buys · 1 sell 1 filing SCTX Scribe Therapeutics Inc. SCTX · 1 buy · 0 sells 1 filing
Recent filings
SCTXPURCHASE Scribe Therapeutics Inc. View filing → $5.0M
333,333 sh × $15.00
Exec Jul 27
Filed Jul 29 · 7:09 PM ET
NAUTSALE Nautilus Biotechnology, Inc. View filing → $11.8M
5,000,000 sh across 2 lots
Exec Jun 2
Filed Jun 4 · 5:30 PM ET